Affinity and epitope profiling of mouse anti-CD40 monoclonal antibodies

被引:17
|
作者
Hager, ACM [1 ]
Ellmark, P [1 ]
Borrebaeck, CAK [1 ]
Furebring, C [1 ]
机构
[1] Lund Univ, Dept Immunotechnol, S-22007 Lund, Sweden
关键词
D O I
10.1046/j.1365-3083.2003.01271.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CD40-CD40L interaction plays a critical role in both humoral and cellular immune responses and interfering antibodies have been suggested as an effective approach for the treatment of lymphomas and autoimmune diseases. In this study we have profiled a panel of mouse antihuman CD40 monoclonal antibodies (MoAbs), regarding their CD40 binding affinity and epitope-specificity relative to the CD40L binding in relation to their cellular activating potential. Despite a rather similar domain-recognition profile, the MoAbs blocked the CD40L binding to a varying degree, with MoAb 5C3 being the poorest inhibitor. There was no correlation between affinity and cellular activation potential. In contrast, a correlation between the ability to block CD40L-binding and activation potential could be seen. We believe that this analysis of several mouse anti-CD40 antibodies can be used to develop strategies for producing new human anti-CD40 antibodies that can more effectively induce or block B-cell proliferation.
引用
收藏
页码:517 / 524
页数:8
相关论文
共 50 条
  • [1] Anti-CD40 monoclonal antibody
    Geldart, T
    Illidge, T
    LEUKEMIA & LYMPHOMA, 2005, 46 (08) : 1105 - 1113
  • [2] ANTI-CD40 MONOCLONAL ANTIBODIES DO NOT INDUCE THROMBOEMBOLISM IN VITRO OR IN VIVO
    Rubic-Schneider, Tina
    Christen, Brigitte
    Flandre, Thierry
    de Billy, Benjamin Cochin
    Cote, Serge
    Nock, Sebastian
    Runser-Loll, Nathalie
    Garcia, Deborah
    Erard, Esther
    Ulrich, Peter
    Rush, James
    TRANSPLANT INTERNATIONAL, 2019, 32 : 205 - 205
  • [3] Conformational regulation in anti-CD40 antibodies
    Orr, C.
    Fisher, H.
    Elliott, I.
    Yu, X.
    Glennie, M.
    White, A.
    Pearson, A.
    Essex, J.
    Cragg, M.
    Tews, I.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2022, 78 : E37 - E37
  • [4] Novel anti-CD40 antibodies demonstrate anti -tumor activity in humanized mouse models
    Guo, Chaoshe
    Yang, Benny
    Ni, Jian
    Guo, Yanan
    Gan, Tian
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Anti-CD40 antibodies in antiphospholipid syndrome (APS)
    Vlachoyiannopoulos, PG
    Mavragani, CP
    Balitsari, A
    Zinzaras, E
    Routsias, JG
    Moutsopoulos, HM
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 126 - 126
  • [6] Epitope mapping and affinity analysis of monoclonal antibodies specific for human CD40L.
    Benjamin, CD
    Hess, D
    Sizing, I
    Wilson, C
    Zafari, M
    Garber, E
    Ehrenfels, B
    Madigan, E
    Hsu, YM
    Lucci, J
    Karpusas, M
    Thomas, D
    TISSUE ANTIGENS, 1996, 48 (4-II): : TC302 - TC302
  • [7] Characterization of an immunosuppressive anti-CD40 ligand monoclonal antibody
    Kim, KM
    Min, HY
    Jung, SH
    Lee, TH
    Kim, JG
    Kang, CY
    HYBRIDOMA, 1998, 17 (05): : 463 - 470
  • [8] Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies
    Schwabe, RF
    Hess, S
    Johnson, JP
    Engelmann, H
    HYBRIDOMA, 1997, 16 (03): : 217 - 226
  • [9] FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
    Lang, Isabell
    Zaitseva, Olena
    Wajant, Harald
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (21)
  • [10] Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties
    Ceglia, Valentina
    Zurawski, Sandra
    Montes, Monica
    Bouteau, Aurelie
    Wang, Zhiqing
    Ellis, Jerome
    Igyarto, Botond Z.
    Levy, Yves
    Zurawski, Gerard
    JOURNAL OF IMMUNOLOGY, 2021, 207 (08): : 2060 - +